Blood-based circulating biomarkers for prediction of immune-checkpoint inhibitors efficacy in renal cell carcinoma

• Principais autores: Loubna Omri (Autor), Marie Naigeon (Autor), Ronan Flippot (Autor), Javier Gavira-Díaz (Autor), Jesus Poveda-Ferriols (Autor), Dan Nguyen (Autor), Chaimae Abdi (Autor), Alvaro Arroyo-Salgado (Autor), Nathalie Chaput (Autor), Guillermo de Velasco (Autor), Laurence Albigès (Autor), Lucía Carril-Ajuria (Autor)
• Formato: Livro
• Publicado em: Open Exploration Publishing Inc., 2024-09-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Immune checkpoint inhibitors (ICI)-based combinations have become the standard first-line treatment for advanced clear cell renal cell carcinoma (ccRCC). Despite significant improvements in survival and the achievement of sustained long-term responses, a subset of patients remains refractory to ICI,...